Clinical Trials Browser

Phase 1/2 × Not yet recruiting × Breast × Clear all

NCT07389733 2026-03-02

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Phase 1/2 Not yet recruiting

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT07441889 2026-03-02

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Phase 1/2 Not yet recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07370506 2026-01-29

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Phase 1/2 Not yet recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07339176 2026-01-14

OP-NEU-101

Phase 1/2 Not yet recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT07336771 2026-01-13

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07136428 2025-12-19

ASCENdANT

Phase 1/2 Not yet recruiting

HER2+ Metastatic Breast Cancer

NCT07292142 2025-12-18

FRIDA

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07260058 2025-12-02

Immune Cell Therapy for Advanced Solid Tumors

Phase 1/2 Not yet recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06027983 2025-09-23

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

Phase 1/2 Not yet recruiting

BreastOther solid neoplasm

HER2+ Advanced Breast Cancer

NCT07177950 2025-09-17

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases

Phase 1/2 Not yet recruiting

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

NCT07164976 2025-09-10

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT05806385 2025-09-09

LOGIC

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04480619 2025-07-16

Shiva

Phase 1/2 Not yet recruiting

Angiogenic Breast Cancer

NCT06788197 2025-03-26

A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06775236 2025-03-19

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT02802423 2025-02-07

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06757335 2025-01-03

A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT04469127 2024-04-10

Heroine01

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06140576 2023-11-20

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06023277 2023-09-05

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms